BioSpace Honors enGene as a 2026 Best Place to Work
enGene Honored by BioSpace as a 2026 Best Place to Work, Underscoring Strong Culture and Mission-Driven Innovation enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic…
QIAGEN Buys Parse Biosciences to Expand Single-Cell Tools
QIAGEN to Acquire Parse Biosciences, Expanding Portfolio into Scalable Single-Cell Sequencing and AI-Driven Discovery QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that it has entered into a definitive agreement…
NMDP to Showcase New Research Driving Improved Transplant Access and Cell Therapy Innovation at ASH 2025
NMDP and CIBMTR to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 2025 NMDP℠, a leading global nonprofit dedicated to advancing cell therapy, and the CIBMTR® (Center…
PharmaJet to Present Intradermal Program Results at ASTMH Meeting
PharmaJet to Showcase Advancements in Intradermal Needle-Free Delivery at ASTMH Annual Meeting PharmaJet®, a leading company focused on transforming injectable delivery through needle-free technology, announced that it will present new…
Zetagen to Share Phase 2 Data on Bone-Metastatic Breast Cancer at SABCS 2025
Zetagen Therapeutics Announces Presentation of Promising Phase 2a Data Demonstrating Complete Responses in Metastatic Breast Cancer Bone Lesions at 2025 SABCS Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company developing…
Serenity Mental Health Launches Ketamine Treatment in Colorado Springs
Serenity Mental Health Centers Expands Access to Breakthrough Ketamine Treatment in Colorado Springs Serenity Mental Health Centers, one of the nation’s fastest-growing providers of advanced psychiatric care, has announced the…
Zoetis Names Kevin Esch as New R&D President, Succeeding Rob Polzer in 2026
Zoetis Appoints Kevin Esch as New R&D President to Succeed Rob Polzer in 2026, Marking a Strategic Leadership Transition in Global Animal Health Innovation Zoetis Inc. (NYSE: ZTS), the world’s…
Vertex Announces Third Quarter 2025 Financial Results
Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today…
Genetix Biotherapeutics to Share U.S. Gene Therapy Patient Experience Data at ASH 2025
Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S.…
PureTech’s Gallop Oncology to Present Phase 1b LYT-200 AML Data at ASH Meeting
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the…
DoseMe Acquires Firstline to Advance Global Infectious Disease Decision Support
DoseMe Expands Precision Dosing Leadership with Strategic Acquisition of Firstline to Deliver Comprehensive Clinical Decision Support in the Global Fight Against Infectious Diseases DoseMe, a global leader in model-informed precision…
Auna S.A. Reports Early Results of Cash Tender Offer and Consent Solicitation for 2029 Notes
Auna S.A. Reports Early Results of Cash Tender Offer and Consent Solicitation for 10.000% Senior Secured Notes Due 2029 Auna S.A. (NYSE: AUNA), a Luxembourg-based public limited liability company and…